Global Sexual
Health Market, by Product Type (Erectile Dysfunction Drugs, Gender
Dysphoria Drugs, Hypoactive Sexual Desire Disorder Drugs, Premature Ejaculation
Drugs, and Others), by Gender (Male and Female), by Distribution Channel
(Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region
(North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
is estimated to be valued at US$
10,289.5 million in 2019, and is expected to exhibit a CAGR of 4.2%,
during the forecast period (2019-2027), as highlighted in a new report published
by Coherent Market Insights.
Major players in the
pharmaceutical industry are focusing on introducing various drugs for treating
sexual dysfunction, which is expected to drive growth of the sexual health
market. For instance, in 2017, Teva Pharmaceutical Industries Ltd. announced
the launch of generic version of Viagra (sildenafil citrate) tablets in the
U.S. indicated for the treatment of erectile dysfunction. Moreover, in
September 2019, Lupin Limited announced the launch of Sildenafil tablets, a
generic version of Pfizer Inc.’s Viagra tablets in the U.S. indicated for the
treatment of erectile dysfunction.
Browse 35 Market Data Tables and
31 Figures spread through 167 Pages and in-depth TOC on 'Global Sexual Health
Market, by Product Type (Erectile Dysfunction Drugs, Gender Dysphoria Drugs,
Hypoactive Sexual Desire Disorder Drugs, Premature Ejaculation Drugs, and
Others), by Gender (Male, and Female), by Distribution Channel (Hospital
Pharmacies, Retail Pharmacies, and Online Pharmacies),, and by Region (North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global
Forecast to 2027'
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/3364
The sexual health market is
expected to witness robust growth owing to increasing initiatives by major
players operating in the market. These players are engaged in adoption of
inorganic growth strategies such as collaborations and partnerships to distribute
their product worldwide, and to increase its consumer base. For instance, in
May 2014, Sanofi entered an acquisition agreement with Eli Lilly and Company to
acquire the rights from the Eli Lilly and Company to apply for regulatory
approval for the nonprescription Cialis (OTC) in the U.S., Europe, Canada and
Australia.
Moreover, increasing approval of
drugs for improving sexual health is expected to drive the global sexual health
market growth during forecast period. For instance, in March 2019, VIVUS, Inc.,
a biopharmaceutical company, received approval from the Ministry of Health of
the Russian Federation for its Avanafil tablet (with strength of 50 mg, 100 mg
and 200 mg tablets) for treatment of erectile dysfunction (ED). The product is
also approved in Jordan, Saudi Arabia, Turkey and the United Arab Emirates
market.
Key Takeaways of the Global
Sexual Health Market:
The global sexual health market
is expected to exhibit a CAGR of 4.2% during the forecast period (2019-2027)
owing to increasing drug launches for the treatment of sexual dysfunction. For
instance, in June 2019, Novitium Pharma LLC receive U.S. FDA approval for its
Sildenafil for Oral Suspension, 10mg/mL, (a generic of Pfizer’s Revatio).
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/sexual-health-market-3364
Increasing clinical trials by key
players for developing novel treatment option for treating sexual dysfunctions
is expected to drive the global sexual health market growth over the forecast
period. For instance, in July 31, 2019, Futura Medical Developments Ltd.
initiated phase 3 clinical trial to demonstrate the efficacy of various doses
of MED2005 (Glyceryl Trinitrate (GTN)) for the treatment of erectile
dysfunction, and to evaluate the long-term efficacy and safety (12 months) of
MED2005. The study is estimated to complete in October 1, 2020.
Major players operating in the
global sexual health market include Teva Pharmaceutical Industries Ltd., Meda
Pharmaceuticals, Inc., Eli Lilly & Company, Bayer AG, Vivus, Inc., Zydus
Pharmaceuticals, IVFTECH APS, Merck & Co., Pfizer Inc., Sun Pharmaceutical Industries
Ltd., Novartis International AG, Mylan Pharmaceuticals Inc., and AstraZeneca.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/3364
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S. Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment